Business Description
Edesa Biotech Inc
NAICS : 325410
SIC : 3741
ISIN : CA85855A3029
Total Employee Number:
17Description
Edesa Biotech Inc is a biotechnology company focused on inflammatory and immune-related diseases. It is involved in exploring novel ways to treat these diseases, including alternatives to topical steroids, which can have side effects. The company's product candidate, EB06, is an anti-CXCL10 monoclonal antibody candidate and is being developed as a therapy for vitiligo, a common autoimmune disorder that causes the skin to lose its color in patches. The other drug candidates in its product pipeline include EB05, EB07, and EB01 which are in their different phases of development.
Financial Strength
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | No Debt | |||||
Equity-to-Asset | 0.82 | |||||
Interest Coverage | No Debt | |||||
Piotroski F-Score | 3/9 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | 47.1 | |||||
3-Year EPS without NRI Growth Rate | 46.8 | |||||
3-Year FCF Growth Rate | 39.6 | |||||
3-Year Book Growth Rate | -51.6 |
Momentum Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 54.37 | |||||
9-Day RSI | 53.03 | |||||
14-Day RSI | 49.81 | |||||
3-1 Month Momentum % | 20.54 | |||||
6-1 Month Momentum % | 371.13 | |||||
12-1 Month Momentum % | 229.56 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 4.76 | |||||
Quick Ratio | 4.76 | |||||
Cash Ratio | 4.57 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -44.2 | |||||
Shareholder Yield % | -4.98 |
Profitability Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
ROE % | -78.79 | |||||
ROA % | -72.64 | |||||
ROIC % | -516.06 | |||||
3-Year ROIIC % | -2157.32 | |||||
ROCE % | -78.56 | |||||
Moat Score | 2 | |||||
Tariff Resilience Score | 8 |
GF Value Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PB Ratio | 35.71 | |||||
EV-to-EBIT | -6.84 | |||||
EV-to-EBITDA | -6.9 | |||||
EV-to-Forward-Revenue | 5.34 | |||||
EV-to-FCF | -9.46 | |||||
| Price-to-Net-Cash | 8.52 | |||||
Earnings Yield (Greenblatt) % | -14.62 | |||||
FCF Yield % | -10.42 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:EDSA
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Edesa Biotech Inc Executives
DetailsGF Valueâ„¢
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | |||
| EPS (TTM) ($) | -1.34 | ||
| Beta | 2.0995 | ||
| 3-Year Sharpe Ratio | 0.51 | ||
| 3-Year Sortino Ratio | 1.64 | ||
| Volatility % | 299.36 | ||
| 14-Day RSI | 49.81 | ||
| 14-Day ATR ($) | 1.132724 | ||
| 20-Day SMA ($) | 6.7215 | ||
| 12-1 Month Momentum % | 229.56 | ||
| 52-Week Range ($) | 0.72 - 20.32 | ||
| Shares Outstanding (Mil) | 9.63 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Edesa Biotech Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Edesa Biotech Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Fourth quarter earnings results for 2026 | 2026-12-11 16:20 | In 163 days | ||
| Annual report for 2026 | 2026-12-11 | In 162 days | ||
| Third quarter earnings results for 2026 | 2026-08-07 | In 36 days | ||
| General meeting for 2026 | 2026-05-27 10:30 | 9.70 (-7.00%) | ||
| Second quarter earnings results for 2026 | 2026-05-14 | 15.24 (+11.32%) | ||
| First quarter earnings results for 2026 | 2026-02-13 | 1.00 (-7.01%) | ||
| Fourth quarter earnings results for 2025 | 2025-12-12 16:20 | 1.77 (-0.56%) | ||
| Annual report for 2025 | 2025-12-12 | 1.77 (-0.56%) | ||
| Third quarter earnings results for 2025 | 2025-08-08 | 2.09 (-2.91%) | ||
| General meeting for 2025 | 2025-05-28 10:30 | 2.01 (+2.55%) |
Show
Entries
Edesa Biotech Inc Frequently Asked Questions
What is Edesa Biotech Inc(EDSA)'s stock price today?
The current price of EDSA is $7.50. The 52 week high of EDSA is $20.32 and 52 week low is $0.72.
When is next earnings date of Edesa Biotech Inc(EDSA)?
The next earnings date of Edesa Biotech Inc(EDSA) is 2026-08-07 Est..
Does Edesa Biotech Inc(EDSA) pay dividends? If so, how much?
Edesa Biotech Inc(EDSA) does not pay dividend.
Guru Commentaries on NAS:EDSA
No articles.
Press Release
Articles on Edesa Biotech Inc
No articles.
Headlines
See More- 1
Jun 11, 2026
Edesa Biotech announces $3.5M PIPE financing
Seeking Alpha • 8:45am
- 1
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers